ライフサイエンスコーパス: mSv

1 (18)F-FSPG was calculated to be 9.5 +/- 1.0 mSv at a patient dose of 300 MBq, which is of similar ma

2 p than in the functional-testing group (10.0 mSv vs. 11.3 mSv), but 32.6% of the patients in the func

3 sure was higher in the CTA group (mean, 12.0 mSv vs. 10.1 mSv; P<0.001).

4 n in 2006 was estimated at approximately 3.0 mSv, an increase of 600% in a single generation.

5 SMA I&T resulted in an effective dose of 3.0 mSv.

6 within 5% of the reference standard (at 5.0 mSv) was marked as the optimal setting.

7 same protocol at a lower total dose (0.5-5.0 mSv, with stepped doses of 0.5 mSv).

8 ination had an average effective dose of 5.0 mSv.

9 -MBq administration of (68)Ga-ABY-025 is 6.0 mSv for LD and 5.6 mSv for HD.

10 generation unit and 2.67 mSv (IQR, 1.68-4.00 mSv) with the first-generation unit (P < .0001).

11 fective dose was reduced to 0.015 +/- 0.0010 mSv/MBq.

12 The mean effective dose was 0.026 +/- 0.0012 mSv/MBq.

13 The effective dose was 0.0326 +/- 0.0018 mSv/MBq.

14 +/- 0.003 mSv/MBq for LD and 0.028 +/- 0.002 mSv/MBq for HD.

15 en, 0.022 +/- 0.002; women, 0.027 +/- 0.002) mSv/MBq.

16 )Ga-labeled tracers, such as 0.021 +/- 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly b

17 The total effective dose was 0.021 +/- 0.003 mSv/MBq for both tracers.

18 Total effective dose was 0.030 +/- 0.003 mSv/MBq for LD and 0.028 +/- 0.002 mSv/MBq for HD.

19 whole-body effective dose estimate of 0.003 mSv/MBq was observed.

20 lculated effective dose was 0.032 +/- 0.0034 mSv/MBq.

21 nd women was estimated to be 0.025 +/- 0.004 mSv/MBq (men, 0.022 +/- 0.004 mSv/MBq; women, 0.027 +/-

22 22 +/- 0.004 mSv/MBq; women, 0.027 +/- 0.004 mSv/MBq).

23 oms were 0.013 +/- 0.004 and 0.014 +/- 0.004 mSv/MBq, respectively, depending on the voiding schedule

24 l subjects (mean +/- SD) was 0.029 +/- 0.004 mSv/MBq.

25 .025 +/- 0.004 mSv/MBq (men, 0.022 +/- 0.004 mSv/MBq; women, 0.027 +/- 0.004 mSv/MBq).

26 ry with an effective dose estimate of 0.0045 mSv/MBq, resulting in 2.68 mSv for a human subject (600-

27 .012 mSv [95% CI confidence interval : 0.005 mSv, 0.031 mSv] for adults).

28 .012 mSv [95% CI confidence interval : 0.006 mSv, 0.022 mSv] for children and 0.012 mSv [95% CI confi

29 0.046 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

30 dose equivalent in millirems (1 mrem = 0.01 mSv) was recorded from personal dosimeters worn on labor

31 ry CTA was calculated as 1.11 mSv (0.47-2.01 mSv) for method A and 8.22 mSv (2.19-12.88 mSv) for meth

32 )(3) His-CNA35 is 3.70 mSv per organ or 2.01 mSv/g of tissue.

33 an estimated human absorbed dose of 2.20E-01 mSv/MBq.

34 The effective dose equivalent was 0.0106 mSv/MBq (0.0392 rem/mCi).

35 d salivary glands (parotids, 0.031 +/- 0.011 mSv/MBq; submandibular, 0.061 +/- 0.031 mSv/MBq).

36 0.006 mSv, 0.022 mSv] for children and 0.012 mSv [95% CI confidence interval : 0.005 mSv, 0.031 mSv]

37 for conventional radiography (median: 0.012 mSv [95% CI confidence interval : 0.006 mSv, 0.022 mSv]

38 e bladder dose was reduced to 0.10 +/- 0.012 mSv/MBq, and the effective dose was reduced to 0.015 +/-

39 , and the effective dose was 0.023 +/- 0.012 mSv/MBq.

40 of A33 directly labeled with (89)Zr (0.0124 mSv/MBq vs. 0.4162 mSv/MBq, respectively).

41 neral conversion coefficient (0.017 or 0.014 mSv.mGy(-1).cm(-1)), determined from Monte Carlo simulat

42 ith an effective dose of approximately 0.014 mSv/MBq.

43 an effective dose conversion factor of 0.014 mSv/mGy cm and reported with size-specific dose estimate

44 spectively, and the effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/m

45 The effective dose was 0.015 mSv/MBq, leading to a radiation burden of 3 mSv when the

46 rgans received doses between 0.008 and 0.015 mSv/MBq, with an effective dose of approximately 0.014 m

47 effective doses were 0.012 mGy/MBq and 0.016 mSv/MBq, respectively.

48 The effective dose was 0.0165 mSv/MBq.

49 The measured effective dose was 0.017 mSv/MBq, with the urinary bladder, osteogenic cells, and

50 The effective dose was estimated to be 0.017 mSv/MBq.

51 to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.

52 sed the effective dose from 0.0908 to 0.0184 mSv/MBq and decreased the uptake in the liver, bone marr

53 The mean effective dose was 0.019 mSv/MBq (0.072 rem/mCi).

54 cents than younger children (0.011 and 0.019 mSv/MBq, respectively; P < 0.0001).

55 The mean effective dose was 2.07E-02 mSv/MBq.

56 The mean effective dose was 1.02 mSv +/- 0.51.

57 effective radiation dose delivered was 15.02 mSv per patient per acute myocardial infarction admissio

58 lated effective dose was 2.4E-02 +/- 0.2E-02 mSv/MBq, corresponding to 3.6 mSv, for a reference activ

59 15 mGy/MBq, and the effective dose was 0.020 mSv/MBq.

60 The effective dose was 0.021 mSv/MBq for males and 0.027 mSv/MBq for females, support

61 ure (effective dose) was approximately 0.021 mSv/MBq.

62 d on extrapolation of mouse data, was 0.0218 mSv/MBq, which would yield a radiation dose of 4 mSv to

63 +/- 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivary glands (parotids, 0.031 +/- 0.011

64 5% CI confidence interval : 0.006 mSv, 0.022 mSv] for children and 0.012 mSv [95% CI confidence inter

65 ation effective dose was approximately 0.023 mSv/MBq.

66 NI-659 effective dose was estimated at 0.024 mSv/MBq.

67 The effective dose was 0.025 mSv/MBq (0.0922 rem/mCi).

68 mSv/MBq), upper large intestine wall (0.0267 mSv/MBq), small intestine (0.0816 mSv/MBq), and liver (0

69 e dose was 0.021 mSv/MBq for males and 0.027 mSv/MBq for females, supporting the feasibility of using

70 sinus rhythm, with a mean difference of 4.03 mSv (95% CI: 0.97, 7.1; P = .01).

71 .011 mSv/MBq; submandibular, 0.061 +/- 0.031 mSv/MBq).

72 5% CI confidence interval : 0.005 mSv, 0.031 mSv] for adults).

73 e interval [ CI confidence interval ]: 0.034 mSv, 0.10 mSv) for children and 0.05 mSv (95% CI confide

74 testines were 0.082, 0.043, 0.042, and 0.035 mSv/MBq, respectively.

75 The estimated effective dose was 0.035 mSv/MBq.

76 determined from whole-body studies was 0.036 mSv/MBq.

77 PPRGD2 was 0.1462 rem/mCi +/- 0.0669 (0.0396 mSv/MBq +/- 0.0181).

78 dose for the investigative protocol was 0.04 mSv (95% confidence interval [ CI confidence interval ]:

79 0.05 mSv (95% CI confidence interval : 0.04 mSv, 0.08 mSv) for adults.

80 ntestine (0.0816 mSv/MBq), and liver (0.0429 mSv/MBq).

81 The effective dose was 0.043 mSv/MBq, resulting in an average of 4.6 mSv per patient.

82 f interest were the bladder (0.102 +/- 0.046 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

83 em/mCi), followed by the heart wall at 0.048 mSv/MBq (0.18 rem/mCi).

84 : 0.034 mSv, 0.10 mSv) for children and 0.05 mSv (95% CI confidence interval : 0.04 mSv, 0.08 mSv) fo

85 The mean effective dose was 0.051 mSv/MBq.

86 with mean effective dose per series of 3.06 mSv (range, 1.4-7.7 mSv).

87 mean absorbed dose was the kidneys at 0.066 mSv/MBq (0.24 rem/mCi), followed by the heart wall at 0.

88 n the spleen (0.250 rem/mCi +/- 0.168 [0.068 mSv/MBq +/- 0.046]) and large intestine (0.529 rem/mCi +

89 h an average effective dose of 0.54 +/- 0.07 mSv/MBq.

90 rbed doses were the thyroid (0.135 +/- 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivar

91 (95% CI confidence interval : 0.04 mSv, 0.08 mSv) for adults.

92 The effective dose was, 2.05, 1.8, 1.08 mSv for brain, abdomen and chest respectively.

93 r two dual-phase cone-beam CT scans was 3.08 mSv.

94 ll (0.0267 mSv/MBq), small intestine (0.0816 mSv/MBq), and liver (0.0429 mSv/MBq).

95 igh radiation doses were the kidneys (0.0830 mSv/MBq), upper large intestine wall (0.0267 mSv/MBq), s

96 effective whole-body dose was 0.61 +/- 0.09 mSv.MBq(-1).

97 the kidneys (0.360 rem/mCi +/- 0.185 [0.098 mSv/MBq +/- 0.050]) and bladder (0.862 rem/mCi +/- 0.436

98 .5 mSv for one PET/CT examination versus 0.1 mSv for one chest radiographic examination.

99 n the rest of the world it was less than 0.1 mSv.

100 r the 4.8-h interval, reduced to 8.3 +/- 1.1 mSv for the 1-h interval.

101 er in the CTA group (mean, 12.0 mSv vs. 10.1 mSv; P<0.001).

102 of (68)Ga-DOTATATE and (68)Ga-DOTATOC is 2.1 mSv for both tracers.

103 ulative effective dose over 3 years was 23.1 mSv (range 1.5 to 543.7 mSv).

104 ackground exposure in the United States (3.1 mSv).

105 C+M and C groups were exposed to 6.8 +/- 4.1 mSv of radiation.

106 e average effective dose coefficient was 5.1 mSv.

107 reduced the effective dose (from 18.5 to 5.1 mSv; P < .001).

108 radiation dose than angiography (9.5 +/- 5.1 mSv; p = 0.005).

109 Effective doses were above 1 mSv y(-1) in the CEZ, but much lower in the rest of Euro

110 lent prognosis, a radiation dose averaging 1 mSv, and a test duration of less than 2 h.

111 high quality images with doses as low as <1 mSv in selected patients who have low heart rates with a

112 those procedures with an effective dose </=1 mSv.

113 e resulted in a maternal effective dose of 1 mSv and an embryo/fetal dose of 0.05 mGy.

114 ngiography examinations (21.5%), less than 1 mSv for 58 (54.2%), and less than 4 mSv for 103 (96.3%).

115 h an effective radiation dose of less than 1 mSv without significant sacrifice of accuracy.

116 ely achieving effective doses of less than 1 mSv, which is well below the average annual dose from na

117 from routine CT examinations to less than 1 mSv.

118 iagnostic quality with a dose of less than 1 mSv.

119 from the FDNPP radionuclides and below the 1 mSv a(-1) benchmark for public exposure.

120 ll Islands (RMI) governments (100 mrem/y = 1 mSv/y).

121 per unit exposure (0.04% versus 0.02% per 1-mSv effective dose for females versus males, respectivel

122 [ CI confidence interval ]: 0.034 mSv, 0.10 mSv) for children and 0.05 mSv (95% CI confidence interv

123 and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv

124 mit for exposure due to radon inhalation (10 mSv).

125 ose of < 0.5 Sv, or at a low dose rate (< 10 mSv/day).

126 estimates for LDIR exposure (OR, 1.10 per 10 mSv; 95% CI, 1.05-1.15) with a possible dose-related res

127 few millisieverts from data greater than 100 mSv, a linear no-threshold model is used, even though su

128 dose for coronary CTA was calculated as 1.11 mSv (0.47-2.01 mSv) for method A and 8.22 mSv (2.19-12.8

129 , 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv)

130 ted radiation dose exposure of 0.29 +/- 0.12 mSv (range 0.16 to 0.53 mSv), yielding 96.9% (436 of 450

131 ht leg were 0.28, 0.28, 0.03, 0.11, and 0.12 mSv, respectively.

132 : 0.31 mSv, 3.90 mSv] for children and 1.12 mSv [95% CI confidence interval : 0.57 mSv, 3.15 mSv] fo

133 cumulative estimated effective dose was 121 mSv (IQR, 81-189; mean, 149 mSv).

134 NPP and ambient radionuclides, of which 0.13 mSv a(-1) (14%) was solely from the FDNPP radionuclides

135 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv

136 effective RE than patients without HCC, 137 mSv (IQR: 87,259) versus 32 mSv (IQR: 13,57), respective

137 ge intestine (0.529 rem/mCi +/- 0.236 [0.143 mSv/MBq +/- 0.064]).

138 ive dose was 121 mSv (IQR, 81-189; mean, 149 mSv).

139 BY-025 yielded a mean effective dose of 0.15 mSv/MBq and was safe, well tolerated, and without drug-r

140 [95% CI confidence interval : 0.57 mSv, 3.15 mSv] for adults) and of the same order of magnitude as t

141 o an approximate median radiation dose of 15 mSv.

142 o an effective radiation dose of 1.5 rem (15 mSv).

143 3 mSv/y, and added exposures of less than 15 mSv are considered low risk for carcinogenesis.

144 R, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mS

145 ne (0.19 mSv/MBq), and small intestine (0.17 mSv/MBq).

146 , 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

147 sments (mean equivalent dose to marrow, 0.18 mSv/MBq).

148 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR,

149 e dose from incorporated (137)Cs of about 18 mSv.

150 , 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and ab

151 (0.27 mSv/MBq), upper large intestine (0.19 mSv/MBq), and small intestine (0.17 mSv/MBq).

152 land of Rongelap (mean = 19.8 mrem/y = 0.198 mSv/y), and relatively high gamma radiation on the islan

153 2.4 mSv for the 4.8-h model and 12.8 +/- 0.2 mSv for the 1-h model.

154 g in the mean per capita effective dose (1.2 mSv vs 2.3 mSv) and the proportion of enrollees who rece

155 t (DLP) was 746 mGy cm (effective dose, 11.2 mSv), with a range of 307-1497 mGy cm (effective dose, 4

156 Bq, the effective dose would be 21.1 +/- 2.2 mSv for the 4.8-h interval, reduced to 8.3 +/- 1.1 mSv f

157 uced with protocol B (2.6 mSv +/- 0.4 vs 3.2 mSv +/- 0.8 with protocol A; P < .0041).

158 imated radiation dose ranged from 3.9 to 5.2 mSv/MBq.

159 Effective doses varied from 0.03 to 69.2 mSv per scan.

160 cation 103 tissue-weighting factors, was 8.2 mSv, using volume scanning with exposure permitting a wi

161 or PET imaging, with a total dose of about 2 mSv for a brain PET/CT protocol.

162 (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv

163 ions, respectively, were as follows: head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR

164 th an average absorbed dose of 2.01 x 10(-2) mSv/MBq (7.43 x 10(-2) rem/mCi).

165 However, a protocol effective dose >20 mSv was proposed as a level requiring particular attenti

166 natural sources), >3 to 20 mSv/year, or >20 mSv/year (upper annual limit for occupational exposure a

167 ; and 3.3 per 1,000 for cumulative doses >20 mSv/year.

168 An effective dose of 20 mSv or higher was delivered by 14% to 25% of abdomen/pel

169 e of receiving an effective dose of >3 to 20 mSv/year was 89.0 per 1,000; and 3.3 per 1,000 for cumul

170 of radiation from natural sources), >3 to 20 mSv/year, or >20 mSv/year (upper annual limit for occupa

171 Radiation dose averaged 2.22 mSv over all patients.

172 11 mSv (0.47-2.01 mSv) for method A and 8.22 mSv (2.19-12.88 mSv) for method B.

173 Sv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

174 08 (1.51-12.36) minutes and 2.15 (0.58-8.22) mSv, respectively.

175 and bladder (0.862 rem/mCi +/- 0.436 [0.233 mSv/MBq +/- 0.118], voiding model) and uptake in the spl

176 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

177 ion doses were highest for gallbladder (0.27 mSv/MBq), upper large intestine (0.19 mSv/MBq), and smal

178 t, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (I

179 e was lower for the CCTA group (24 versus 29 mSv; P < 0.001).

180 ve dose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

181 Mean effective dose was 4.3 +/- 0.3 mSv/patient (range, 3.7-4.9 mSv).

182 vely, were as follows: head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); ch

183 - 2.0 mGy, 148 +/- 85 mGycm, and 2.2 +/- 1.3 mSv) were significantly lower than for FBP CT (8.5 +/- 3

184 functional-testing group (10.0 mSv vs. 11.3 mSv), but 32.6% of the patients in the functional-testin

185 mSv) compared with standard protocols (19.3 mSv; P<0.0001).

186 ), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 m

187 an per capita effective dose (1.2 mSv vs 2.3 mSv) and the proportion of enrollees who received high (

188 ased on 150 MBq of (68)Ga-pentixafor was 2.3 mSv.

189 ation dose from additional sequences was 4.3 mSv per patient.

190 e estimates yielded an effective dose of 6.3 mSv for an injected activity of 200 MBq of (64)Cu-DOTATA

191 lower (a "reduced dose") (effective dose, 3 mSv), and only 10% of institutions kept DLP at 400 mGy c

192 ; mean, 6.5) were high-dose procedures (>/=3 mSv; ie, 1 year's background radiation), including 1 (IQ

193 radiation exposure in the United States is 3 mSv/y, and added exposures of less than 15 mSv are consi

194 An imaging protocol with effective dose </=3 mSv is considered very low risk, not warranting extensiv

195 mSv/MBq, leading to a radiation burden of 3 mSv when the clinical target dose of 200 MBq was used.

196 adiation exposure to effective doses < or =3 mSv/year (background level of radiation from natural sou

197 higher than typical background radiation (3 mSv/year).

198 ffective dose can be reduced to 4.5 +/- 0.30 mSv (at 300 MBq), with a bladder-voiding interval of 0.7

199 provided an effective dose of less than 0.30 mSv/MBq, with the gallbladder as the critical organ; the

200 0.52 mSv [95% CI confidence interval : 0.31 mSv, 3.90 mSv] for children and 1.12 mSv [95% CI confide

201 s 17.7 mSv for the first 4 patients and 8.31 mSv for the last 9 patients.

202 , 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

203 without HCC, 137 mSv (IQR: 87,259) versus 32 mSv (IQR: 13,57), respectively.

204 ivered mean radiation doses of 5.56 and 3.33 mSv, respectively (P < .05).

205 n chest radiation exposure (0.06 versus 0.34 mSv; P=0.037, Mann-Whitney U test) and lower median cost

206 an average radiation-absorbed dose of 0.394 mSv/MBq.

207 for the 4.8-h model, reducing to 8.3 +/- 0.4 mSv for the 1-h model.

208 fective dose to humans would be 22.2 +/- 2.4 mSv for the 4.8-h model and 12.8 +/- 0.2 mSv for the 1-h

209 3.7 mGy, 365 +/- 160 mGycm, and 5.5 +/- 2.4 mSv).

210 on doses were calculated to be 2.64 and 26.4 mSv for FPA and MSM techniques, respectively.

211 ith current radiation exposures (median, 3.4 mSv), breast shielding yielded a 33% increase in image n

212 dow, 5.8 mSv with optimized exposure and 4.4 mSv for optimized 100-kVp scanning.

213 re as follows: head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 m

214 MBq, which would yield a radiation dose of 4 mSv to a patient after injection of 185 MBq of (68)Ga-NO

215 s than 1 mSv for 58 (54.2%), and less than 4 mSv for 103 (96.3%).

216 respectively, with an effective dose of 0.41 mSv/MBq (1.5 rem/mCi).

217 beled with (89)Zr (0.0124 mSv/MBq vs. 0.4162 mSv/MBq, respectively).

218 dard deviation] and 0.78 mSv +/- 0.2 vs 0.44 mSv +/- 0.1; P < .0001), respectively, for the 80- and 1

219 t significantly reduced radiation dose (0.44 mSv) and contrast medium volume (45 mL), thus enabling s

220 verall, the radiation dose was less than 0.5 mSv for 23 of the 107 CT angiography examinations (21.5%

221 dose (0.5-5.0 mSv, with stepped doses of 0.5 mSv).

222 pective doses were found to be less than 0.5 mSv, whereas in the rest of the world it was less than 0

223 the first 3 months was estimated between 1-5 mSv in Fukushima and the neighboring prefectures.

224 a total effective dose of approximately 1.5 mSv.

225 ythm and atrial fibrillation (1.4 versus 1.5 mSv; P=0.22).

226 Mean exposure to ionising radiation was 12.5 mSv (SD 4.1) for (18)F-FDG PET/CT compared with zero for

227 ective dose equivalent of approximately 13.5 mSv, roughly equivalent to a clinical [(18)F]-FDG proced

228 ionizing radiation was estimated to be 14.5 mSv for one PET/CT examination versus 0.1 mSv for one ch

229 At 2.5 mSv, the maximum mean differences in values from those o

230 CT perfusion protocol can be lowered to 2.5 mSv, with only minor quantitative effects on perfusion v

231 of 307-1497 mGy cm (effective dose, 4.6-22.5 mSv) for mean DLPs.

232 exposure may seem small at approximately 3-5 mSv/year, which is only slightly higher than typical bac

233 proportion of healthy patients exposed to >5 mSv chest radiation.

234 The proportion with >5 mSv to the chest and no significant cardiopulmonary diag

235 eived high annual radiation exposure (>20-50 mSv) and 3.9% received very high annual exposure (>50 mS

236 rtion of enrollees who received high (>20-50 mSv) exposure (1.2% vs 2.5%) and very high (>50 mSv) ann

237 ) exposure (1.2% vs 2.5%) and very high (>50 mSv) annual radiation exposure (0.6% vs 1.4%).

238 3.9% received very high annual exposure (>50 mSv).

239 r wall (0.62 mSv/MBq) and the pancreas (0.51 mSv/MBq).

240 Median annualized effective RE was 51 mSv (interquartile range [IQR]: 19,126), with 10% expose

241 han those with conventional CT (median: 0.52 mSv [95% CI confidence interval : 0.31 mSv, 3.90 mSv] fo

242 ure of 0.29 +/- 0.12 mSv (range 0.16 to 0.53 mSv), yielding 96.9% (436 of 450) interpretable segments

243 fective dose due to (124)I-BTT-1023 was 0.55 mSv/MBq, if blockage of thyroid uptake is assumed.

244 1.12 mSv [95% CI confidence interval : 0.57 mSv, 3.15 mSv] for adults) and of the same order of magn

245 r-patient was higher in DURING_Tl-201 (23.57 mSv; 95% confidence interval, 23.16-23.96) than in Tc-99

246 Bq, the effective dose would be 17.2 +/- 0.6 mSv for the 4.8-h model, reducing to 8.3 +/- 0.4 mSv for

247 iation dose was reduced with high-pitch (1.6 mSv) compared with standard protocols (19.3 mSv; P<0.000

248 Mean effective radiation dose was 14.6 mSv.

249 s significantly reduced with protocol B (2.6 mSv +/- 0.4 vs 3.2 mSv +/- 0.8 with protocol A; P < .004

250 02 +/- 0.2E-02 mSv/MBq, corresponding to 3.6 mSv, for a reference activity of 150 MBq.

251 .043 mSv/MBq, resulting in an average of 4.6 mSv per patient.

252 of (68)Ga-ABY-025 is 6.0 mSv for LD and 5.6 mSv for HD.

253 ns kept DLP at 400 mGy cm (effective dose, 6 mSv) or less in at least 50% of patients.

254 ed doses were the urinary bladder wall (0.62 mSv/MBq) and the pancreas (0.51 mSv/MBq).

255 Sv) with the second-generation unit and 2.67 mSv (IQR, 1.68-4.00 mSv) with the first-generation unit

256 stimate of 0.0045 mSv/MBq, resulting in 2.68 mSv for a human subject (600-MBq dose).

257 tion dose from CAC acquisition was 1.4+/-0.7 mSv.

258 was seen with sinus rhythm (1.5 versus 16.7 mSv; P<0.0001) but was more profound with atrial fibrill

259 The effective dose from PET/CTE was 17.7 mSv for the first 4 patients and 8.31 mSv for the last 9

260 all median cumulative effective dose was 2.7 mSv (range, 0.1-76.9 mSv), and the associated lifetime a

261 ation exposure (5.5 +/- 4.4 vs. 12.5 +/- 2.7 mSv, P < 0.0001).

262 nd with atrial fibrillation (1.9 versus 27.7 mSv; P=0.039).

263 would result in a mean effective dose of 3.7 mSv using the weighting factors of the ICRP 103-only sli

264 nd the effective dose varied from 2.4 to 3.7 mSv.

265 se of 7.7 mSv, which could be reduced to 5.7 mSv with frequent bladder voids.

266 similar magnitude to that of (18)F-FDG (5.7 mSv).

267 ver 3 years was 23.1 mSv (range 1.5 to 543.7 mSv).

268 dose per series of 3.06 mSv (range, 1.4-7.7 mSv).

269 86-7548 results in an effective dose of 7.7 mSv, which could be reduced to 5.7 mSv with frequent bla

270 200 MBq for (64)CuCl2 translated into a 5.7-mSv effective dose.

271 500 MBq of (99m)Tc-(CO)(3) His-CNA35 is 3.70 mSv per organ or 2.01 mSv/g of tissue.

272 93 mSv (interquartile range [IQR], 0.58-1.74 mSv) with the second-generation unit and 2.67 mSv (IQR,

273 92 mSv +/- 0.3 [standard deviation] and 0.78 mSv +/- 0.2 vs 0.44 mSv +/- 0.1; P < .0001), respectivel

274 coefficient resulted in a dose as low as 1.8 mSv, substantially underestimating effective dose for bo

275 CTA/CTP (7.9 +/- 2.8 mSv) had a significantly lower effective radiation dose

276 head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13

277 permitting a wide reconstruction window, 5.8 mSv with optimized exposure and 4.4 mSv for optimized 10

278 e island of Bikini (mean = 184 mrem/y = 1.84 mSv/y).

279 1 mSv) for method A and 8.22 mSv (2.19-12.88 mSv) for method B.

280 The median radiation dose with CCTA was 5.88 mSv (n = 1039; confidence interval: 5.2 to 6.4).

281 The mean effective dose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

282 The mean patient dose was 2.7 +/- 0.9 mSv/patient.

283 was low in both multidetector CT groups (1.9 mSv+/-0.2).

284 was 4.3 +/- 0.3 mSv/patient (range, 3.7-4.9 mSv).

285 esult in an effective dose equivalent of 5.9 mSv (0.59 rem) and a lung dose of 21.8 mGy (2.18 rad) in

286 The effective dose was estimated at 6.9 mSv for a 370-MBq (18)F-FTT dose in humans.

287 effective dose was 2.7 mSv (range, 0.1-76.9 mSv), and the associated lifetime attributable risk of c

288 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv

289 effective radiation dose was 1.4 (1.3, 1.9) mSv, with no difference between sinus rhythm and atrial

290 [95% CI confidence interval : 0.31 mSv, 3.90 mSv] for children and 1.12 mSv [95% CI confidence interv

291 effective dose was 75% and 108% higher (0.92 mSv +/- 0.3 [standard deviation] and 0.78 mSv +/- 0.2 vs

292 interval, 23.16-23.96) than in Tc-99m (12.92 mSv; 95% confidence interval, 12.55-13.40; P<0.001).

293 The median radiation dose was 0.93 mSv (interquartile range [IQR], 0.58-1.74 mSv) with the

294 mmitted effective dose of approximately 0.95 mSv a(-1) from combined FDNPP and ambient radionuclides,

295 Mean radiation dose was 1.98 mSv +/- 0.16 (standard deviation) for each cardiac CT ac

296 whom radiation effective dose averaged 0.99 mSv and study duration, 117 min.

297 The individual organ doses (mSv/MBq) were 0.40 +/- 0.058 for the urinary bladder wal

298 Radiation exposure is reported in mSv, a standardized measure of the detrimental biologic

299 adiation exposure measured in millisieverts (mSv) and medical charges for the respective diagnostic p

300 Mean dose values (mSv) reported from anterior parts of the phantom section

301 rem/year (mrem/y) = 0.076 millisievert/year (mSv/y)], larger levels of gamma radiation for the island